ReviewBlood advances2026
Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.
Review in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe treatment landscape for multiple myeloma is evolving rapidly with the integration of novel B-cell maturation antigen (BCMA)-directed therapies. In the early-relapse setting (1-3 prior lines of therapy), several practice-changing phase 3 trials have reported results in the past 2 years, including chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates. These studies offer exciting new options for clinicians but also introduce complexity due to differences in patient populations, trial designs, and real-world applicability. We synthesize data from trials exploring BCMA-directed immunotherapy in the early-relapse setting, explore nuances in trial characteristics and their implications for treatment selection, and discuss treatment decision determinants, including age, fitness, comorbidities, treatment exposure, and access to therapy. We subsequently discuss how emerging BCMA-directed therapy affects decision-making in several common scenarios. For each of these common scenarios, we explore applicability and limitations from the clinical trials, treatment access, and logistical considerations and the importance of shared decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.